Abstract 827P
Background
An expanding number of genes predisposing to hematologic malignancies are being discovered by next-generation sequencing (NGS) technology. The 5th edition of the World Health Organization and International Consensus Classification revised their classification of hematologic neoplasms with germline predisposition acknowledging this development. We aimed to identify the mutational spectrum of germline predisposition in hematologic malignancies from Korean patients.
Methods
The study included 444 patients tested for hematologic malignancy panel testing at Pusan National University Yangsan Hospital from January 2019 to December 2022. The assay consisted of 200 genes related to hematologic malignancies and was performed with NGS on genomic DNA extracted from bone marrow specimens or peripheral blood. We identified potential germline variants by retrospective analysis of NGS results. Variant allele frequency > 0.3 of pathogenic or likely pathogenic variants in a known germline predisposition gene was considered potential germline variants. We could not confirm each variant's germline status due to the absence of cultured skin fibroblast specimens.
Results
Thirty-seven (8.33%) patients harbored 38 potential germline variants. DDX41 (21.62%, 8 patients), RUNX1 (10.81%, 4 patients), GATA2 (10.81%, 4 patients), and PAX5 (10.81%, 4 patients) were the most common genes. One patient had 2 variants in the SBDS gene, a compound heterozygote. Frameshift (18 variants, 47.37%) and missense (10 variants, 26.32%) were the main proportion of the 38 potential germline variants.
Conclusions
We found that DDX41, RUNX1, GATA2, and PAX5 are the most common genes in potential germline variants in hematologic malignancies in Korea. This study provides insight into the pathophysiology of germline predisposition in hematologic malignancies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18